ES2140380T3 - Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas. - Google Patents

Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas.

Info

Publication number
ES2140380T3
ES2140380T3 ES91104432T ES91104432T ES2140380T3 ES 2140380 T3 ES2140380 T3 ES 2140380T3 ES 91104432 T ES91104432 T ES 91104432T ES 91104432 T ES91104432 T ES 91104432T ES 2140380 T3 ES2140380 T3 ES 2140380T3
Authority
ES
Spain
Prior art keywords
particles
protease
gag
vaccine
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91104432T
Other languages
English (en)
Other versions
ES2140380T5 (es
Inventor
Hans Prof Dr Wolf
Holger Dipl-Biol Fliessbach
Brunn Albrecht Dr V
Ralf Dipl-Biol Wagner
Manfred Dr Motz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WOLF HANS JOACHIM PROF DR
Original Assignee
WOLF HANS JOACHIM PROF DR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8203785&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2140380(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by WOLF HANS JOACHIM PROF DR filed Critical WOLF HANS JOACHIM PROF DR
Publication of ES2140380T3 publication Critical patent/ES2140380T3/es
Application granted granted Critical
Publication of ES2140380T5 publication Critical patent/ES2140380T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ESTRATEGIAS DE VACUNAS DEL VIH-1 CONVENCIONALES, BASADAS EN LA PARTE EXTERNA DE LA PROTEINA ENV GP160/120, NO HAN SIDO HASTA AHORA CAPACES DE INDUCIR UNA INMUNIDAD PROTECTORA. ADEMAS, ANTICUERPOS REALZADOS PUEDEN INFLUENCIAR NEGATIVAMENTE LA PROGRESION DE LA ENFERMEDAD. DEBIDO A LA APARICION TEMPRANA EN LA INFECCION Y SU NATURALEZA PARTICULAR, LA PROTEINA P55-GAG DEL NUCLEO DEL VIRUS PARECE SER UN CANDIDATO A VACUNA QUE PROMETE. LA EXPRESION P55-NUCLEO FUE ENSAYADA MEDIANTE UNA COMBINACION DE VACUNA Y VIRUS BACULO. EL VERTIDO DE LAS PARTICULAS DE NUCLEO 90-110 NM EN UN MEDIO DE CULTIVO FUE OBSERVADA EN AMBOS SISTEMAS DE EXPRESIONES Y PROBADOS MEDIANTE UN MICROSCOPIO DE ELECTRON DE SECCION ULTRADELGADA Y ANALISIS DE SEDIMENTACION. LA ADICION DE LA SECUENCIA CODIFICADA DE PROTEASA EN UN PROCESO EFICIENTE DE LA MOLECULA PRECURSORA P55ACULO . PROTEASA SIGNIFICANTE MEDIANTE EL PROCESO DEL PRECURSOR GAG EN EL SISTEMA-VACCINIA QUE SOLO ALCANZADA POR LA ADICION DE LA SECUENCIA CODIFICADA POL ENTERA. EN CONTRASTE CON OTROS RETROVIRUS (MMLV), PROTEASA VIH-1 MEDIATIZADA PROCESADA NO DEPENDE DE LA MIRISTILACION DE P55-GAG. UN PROCESO MEDIATIZADO DE PROTEASA NO COMPLETA EL PROCESO DE MADURACION DE LAS PARTICULAS DE PRECURSOR-P55, PERO EN CONTRASTE, INHIBE LA FORMACION DE PARTICULAS, OTRAS INVESTIGACIONES ENFOCADAS EN LA APLICACION DE PARTICULAS-P55-GAG PREMATURAS. PARA EXTENDER SU ESPECTRO INMUNOLOGICO, UNA SECUENCIA CONSENSUADA DEL MAYOR VIH EPITOPE V3 DE GP120 QUE NEUTRALIZA, DISEÑADO EN NUESTRO LABORATORIO, FUE INSERTADO EN DIFERENTES ZONAS DE LA MOLECULA PORTADORA P55. LA EXPRESION DE LAS PROTEINAS QUIMERICAS P55/V3 EN E. COLI Y EL SISTEMA DE EXPRESION VACCINIA FUE PROBADO POR EL ANALISIS WESTERN BLOT, UTILIZANDO (I) ANTICUERPOS MONOCLONALES DIRIGIDOS A P55 Y LA ZONA V3 INSERTADA Y (II) SERA PEPTIDO MONOESPECIFICO ANTI-V3. PARTICULAS HIBRIDAS P55/V3 SERAN PURIFICADAS DESDE CELULAS INFECTADAS DE BACULOVIRUS. LOS VIRUS DE VACCINIA P55/V3 RECOMBINANTES SON, EN ADICION A LA PRODUCCION DEANTIGENOS, UTILIZADOS DIRECTAMENTE COMO UNA VACUNA VIVA EN ANIMALES EXPERIMENTALES.
ES91104432T 1990-03-21 1991-03-21 Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas. Expired - Lifetime ES2140380T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90105319 1990-03-21
EP90105319 1990-03-21

Publications (2)

Publication Number Publication Date
ES2140380T3 true ES2140380T3 (es) 2000-03-01
ES2140380T5 ES2140380T5 (es) 2005-03-16

Family

ID=8203785

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91104432T Expired - Lifetime ES2140380T5 (es) 1990-03-21 1991-03-21 Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas.

Country Status (5)

Country Link
EP (1) EP0449116B2 (es)
AT (1) ATE183235T1 (es)
DE (1) DE69131513T3 (es)
ES (1) ES2140380T5 (es)
GR (1) GR3031817T3 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773211A (en) * 1991-07-10 1998-06-30 Abbott Laboratories Differentiation of HTLV-I and HTLV-II using synthetic peptides
EP0565794A1 (en) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction of CTL responses
GB9208218D0 (en) * 1992-04-14 1992-05-27 British Bio Technology Hybrid particles
EP0572737B1 (en) * 1992-06-04 2001-02-28 The Research Foundation For Microbial Diseases Of Osaka University HIV Gag-env fusion antigen
AU6829494A (en) * 1993-08-02 1995-02-28 Chiron Corporation Recombinant constructs using replacement sequences in hypervariable regions
AU744882B2 (en) * 1997-03-11 2002-03-07 Mayo Foundation For Medical Education And Research Compositions and methods for elimination of unwanted cells
EP1141313A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
PT1141315E (pt) 1998-12-31 2008-05-05 Novartis Vaccines & Diagnostic Polipéptidos do envelope (env) de hiv modificados
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1311686A2 (en) 2000-08-14 2003-05-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
JP5033303B2 (ja) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
EP2280074A3 (en) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
CA2458995C (en) 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
WO2006050394A2 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
US8620059B2 (en) 2007-12-13 2013-12-31 Fpinnovations Characterizing wood furnish by edge pixelated imaging
US20140004146A1 (en) * 2011-03-17 2014-01-02 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Method for producing virus-like particle by using drosophila cell and applications thereof
EP2694101B1 (en) 2011-04-06 2016-09-14 Biovaxim Limited Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
EP3158058B1 (en) 2014-06-18 2019-04-17 MorphoSys AG Fusion proteins and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
ES2059823T3 (es) * 1988-05-06 1994-11-16 Ferropas Ag Metodos y sistemas para producir antigenos de hiv.

Also Published As

Publication number Publication date
DE69131513T3 (de) 2005-05-25
EP0449116A1 (en) 1991-10-02
ES2140380T5 (es) 2005-03-16
DE69131513T2 (de) 2000-05-04
ATE183235T1 (de) 1999-08-15
GR3031817T3 (en) 2000-02-29
DE69131513D1 (de) 1999-09-16
EP0449116B2 (en) 2004-08-25
EP0449116B1 (en) 1999-08-11

Similar Documents

Publication Publication Date Title
ES2140380T3 (es) Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas.
NO921969L (no) Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener
DK33190D0 (da) Hiv-3 retrovirus og anvendelse heraf
ES2099066T3 (es) Antigenos a partir de adn sintetico derivado del virus de la inmunodeficiencia humana (hiv-1).
JPH11322792A (ja) ヒト免疫不全レトロウイルス（ウイルスｈｉｖ）に対して誘導された抗体により認識できるペプチド、及び前記ウイルスの或る種に起因する感染の診断、場合によってはエイズに対するワクチン接種における該ペプチドの使用。
AP368A (en) Derivatives of gp160 and vaccine based on gp160 or a derivative thereof, containing an adjuvant.
HUP0002176A2 (hu) Vakcinákban vagy diagnosztikai vizsgálatokban alkalmazható PRRSV-peptidszekvenciákat azonosító PRRSV-antigénhelyek
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
WO1989002277A2 (en) Prophylaxis and therapy of acquired immunodeficiency syndrome
AR032871A1 (es) Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana
FI885296A0 (fi) Rekombinant hiv-2 polypeptid.
BR9204851A (pt) Antigeno de HIV e processo para sua produçao molécula de DNA recombinante, reagente para diagnóstico e vacina para sindrome da imunodeficiência adquirida
AU654970B2 (en) Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant
US5876724A (en) Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
EP0472706B1 (en) Induction of protection against viral infection
Saitoh et al. A unique monoclonal antibody that recognizes mature p17 of HIV-1 but not its precursor
MY104530A (en) Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.
Girard et al. Candidate vaccines for HIV
TH9629EX (th) โพรเทเอส, รีเวอร์ส แทรนส์คริพเทส และเอนโดนิวคลี เอสของ ของเรโทรไวรัส และวิธีการสำหรับผลิตเอนไซม์เหล่า นี้
TH13136EX (th) แอนติเจนของ hiv
DE3709449A1 (de) Herstellung traeger-gebundener synthetischer peptide zur verwendung als antigen in diagnostischen testen und zur erzeugung spezifischer immunantwort
FR2730243A1 (fr) Polypeptides de glycoproteine trasmembranaire d'enveloppe du retrovirus humain du type hiv-1 et polypeptides presentant avec eux une parente immunologique

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 449116

Country of ref document: ES